Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1CNS 1

Conditions

Urinary Bladder Neoplasms 1Small Cell Lung Carcinoma 1Recurrence 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Polycystic Ovary Syndrome 1Non-Muscle Invasive Bladder Neoplasms 1Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Multiple Myeloma 1Lung Neoplasms 1Lower Urinary Tract Symptoms 1Leukemia, Myeloid, Acute 1Leukemia, Biphenotypic, Acute 1Carcinoma, Non-Small-Cell Lung 1Brain Neoplasms 1Adenocarcinoma of Lung 1

Interventions

Carboplatin 361Pemetrexed 276Cisplatin 230Paclitaxel 213Docetaxel 205Gemcitabine 160Erlotinib Hydrochloride 150Bevacizumab 132pembrolizumab 129Radiotherapy 114Nivolumab 88durvalumab 84Drug Therapy 84osimertinib 82atezolizumab 58Vinorelbine 53Gefitinib 53Radiosurgery 50Cetuximab 39Taxes 37130-nm albumin-bound paclitaxel 36Ipilimumab 34anlotinib 33Surgical Procedures, Operative 33Magnetic Resonance Spectroscopy 33Etoposide 30Albumin-Bound Paclitaxel 29tislelizumab 27icotinib 27aflutinib 26

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Carcinoma, Non-Small-Cell Lung × Capsules × Clear all
NCT03753685 2025-07-23

X-396(Ensartinib) Capsules in ALK-Positive NSCLC Patients With Brain Metastases

Fudan University

Phase 2 Active not recruiting
27 enrolled
CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡